Skip to content
10-K

Annual Report

INHIBRX BIOSCIENCES, INC. INBX

0002007919-26-000006

← back to feed
Filed
Mar 19, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2025 · Mar 11, 2026 14.61M sh
Shares Diluted FY 2025 · Dec 31, 2025 15.49M sh
Shares Diluted FY 2025 · Dec 31, 2024 14.98M sh
Capex FY 2025 · Dec 31, 2025 $31K
Capex FY 2025 · Dec 31, 2024 $2.6M
Operating Cash Flow FY 2025 · Dec 31, 2025 −$129.79M
Operating Cash Flow FY 2025 · Dec 31, 2024 −$194.41M
Long Term Debt FY 2025 · Dec 31, 2025 $100.56M
Long Term Debt FY 2025 · Dec 31, 2024 $0
Cash And Equivalents FY 2025 · Dec 31, 2025 $124.22M
Cash And Equivalents FY 2025 · Dec 31, 2024 $152.6M
Stockholders Equity FY 2025 · Dec 31, 2025 $7.99M
Stockholders Equity FY 2025 · Dec 31, 2024 $133.58M
Stockholders Equity FY 2025 · Dec 31, 2023 $43.5M
Current Liabilities FY 2025 · Dec 31, 2025 $33.8M
Current Liabilities FY 2025 · Dec 31, 2024 $40.73M
Total Liabilities FY 2025 · Dec 31, 2025 $138.49M
Total Liabilities FY 2025 · Dec 31, 2024 $47.18M
Current Assets FY 2025 · Dec 31, 2025 $132.83M
Current Assets FY 2025 · Dec 31, 2024 $160.4M
Total Assets FY 2025 · Dec 31, 2025 $146.48M
Total Assets FY 2025 · Dec 31, 2024 $180.77M
Eps Diluted FY 2025 · Dec 31, 2025 −$9.04
Eps Diluted FY 2025 · Dec 31, 2024 $112.62
Eps Basic FY 2025 · Dec 31, 2025 −$9.04
Eps Basic FY 2025 · Dec 31, 2024 $114.01
Sga Expense FY 2025 · Dec 31, 2025 $23.3M
Sga Expense FY 2025 · Dec 31, 2024 $127.91M
Rd Expense FY 2025 · Dec 31, 2025 $113.03M
Rd Expense FY 2025 · Dec 31, 2024 $203.74M
Net Income FY 2025 · Dec 31, 2025 −$140.06M
Net Income FY 2025 · Dec 31, 2024 $1.69B
Operating Income FY 2025 · Dec 31, 2025 −$135.03M
Operating Income FY 2025 · Dec 31, 2024 −$331.45M
Revenue FY 2025 · Dec 31, 2025 $1.3M
Revenue FY 2025 · Dec 31, 2024 $200K